Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice
Sergey V. Novoselov(Energy Institute), Vadim N. Gladyshev(Brigham and Women's Hospital), Valentina M. Factor, Diego F. Calvisi(University of Regensburg), Bradley A. Carlson(National Cancer Institute), Dolph L. Hatfield(Northwestern University), Vyacheslav M. Labunskyy(Boston University), Dmitri E. Fomenko(University of Nebraska–Lincoln), Mohamed E. Moustafa(National Institutes of Health)
Cited by 121
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Selenoproteins: Molecular Pathways and Physiological Roles
|Physiological Reviews|2014|1.4k
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
|Gastroenterology|2006|726
Selenium and selenocysteine: roles in cancer, health, and development
|Trends in Biochemical Sciences|2014|704